Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

2(50.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 4(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT06967753Phase 4Recruiting

Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

Role: collaborator

NCT05005156Phase 2Completed

Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV

Role: collaborator

NCT03564184Not ApplicableCompleted

Longitudinal Study of Music Therapy's Effectiveness for Premature Infants and Their Caregivers

Role: collaborator

NCT03731429Phase 4Unknown

Lidocaine to Prevent Cough and Hemodynamic Changes in Tracheal Extubation

Role: lead

All 4 trials loaded